Followers | 65 |
Posts | 4647 |
Boards Moderated | 0 |
Alias Born | 02/12/2013 |
Friday, November 20, 2020 12:36:42 PM
TODAY @REALDONALDTRUMP WILL RUIN AMAZON PHARMACY DREAMS.
At most stops, however, Trump has at least attempted to broach one topic that pollsters have repeatedly found to be resonant with voters: the high cost of prescription drugs. And time and again, Trump has not only promised to cut them – “Drug prices will be coming down 80 or 90 percent,” he said during the first presidential debate – but insisted that, functionally, he has already done so.
It’s a strong claim in an election year. Is there hard evidence to support it?
“Evidence exists – but it’s to the contrary,” said Anthony Wright, executive director of Health Access California, a consumer advocacy group. “Drug prices continue to go up and up, and what’s remarkable is how true that is across the board. Newer drugs, older ones, brand names, generics – the prices for all of them are climbing.”
Drug prices in the U.S. rose by 3% from 2018 to 2019, part of a 4.6% overall increase in the cost of medical care.
So say the numbers, Trump’s bluster to the contrary. According to the Bureau of Labor Statistics, drug prices in the U.S. rose by 3% from 2018 to 2019, part of a 4.6% overall increase in the cost of medical care in this country. By July of this year, the prescription cost site GoodRx had recorded an average price hike of nearly 7% among more than 850 brand and generic drugs for 2020.
The issue has an urgency that goes beyond the ballot. In a year of the coronavirus pandemic, with millions of Americans out of work and either absent health insurance or about to be cut from employers’ plans, every hint of a rise in costs feels epic – and continuing increases could be devastating for low and middle income families alike. But even coming into the election cycle, before COVID-19 dominated the conversation, prescription drug prices were near the top of voters’ concerns about health care. - source
Recent GDRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 12:01:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2024 11:59:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 09:05:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 09:00:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:43:17 PM
- GoodRx to Participate in Upcoming Investor Conferences • Business Wire • 08/21/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:40:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:26:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 09:14:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 05:14:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 10:52:42 AM
- GoodRx Reports Second Quarter 2024 Results • Business Wire • 08/08/2024 10:05:00 AM
- Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira® • PR Newswire (US) • 07/18/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 10:26:05 PM
- GoodRx Announces Date for Second Quarter 2024 Earnings Release and Conference Call • Business Wire • 07/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 07:38:57 PM
- Ian T. Clark Joins GoodRx Board of Directors • Business Wire • 07/10/2024 01:00:00 PM
- GoodRx Launches New “Prescription Cost Tracker” to Spotlight Key Factors Driving Out-of-Pocket Medication Costs in the U.S. • Business Wire • 06/26/2024 01:00:00 PM
- GoodRx Holdings, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before June 21, 2024 to Discuss Your Rights - GDRX • PR Newswire (US) • 06/20/2024 09:45:00 AM
- The Gross Law Firm Reminds GoodRx Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 21, 2024 - GDRX • PR Newswire (US) • 06/17/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 12:52:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 12:51:30 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 06/11/2024 11:01:15 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 06/11/2024 11:00:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 11:02:52 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM